Tavneos - direct healthcare professional communication (DHPC)

avacopan

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Tavneos (avacopan) – recommendation for revocation of the marketing authorisation in the EU due to unfavourable benefit-risk balance

Dissemination date: 16/07/2026

Key facts

• Medicine name:
  Tavneos
• Active substance:
  avacopan
• Therapeutic area (MeSH):
  • Microscopic Polyangiitis
  • Wegener Granulomatosis
• Procedure number:
  EMA/REF/0000325221
• Regulatory outcome:
  Revocation
• DHPC type:
  Referral - Article 20 procedure
• Human ATC codes:
  L04
• Dissemination date:
  16/07/2026